CME Information
Description
This is a certified continuing medical education (CME) activity that focuses on the biologic, diagnostic, and therapeutic aspects of Hodgkin lymphoma and non-Hodgkin lymphoma. The format of the meeting includes a combination of expert presentations, interactive case discussions, poster and abstract presentations, and an opportunity for question-and-answer debates. Additionally, the entire conference will be certified for nursing continuing education credits.
The goal of this educational activity is to facilitate a forum for physicians, nurses, researchers, and other healthcare professionals to discuss biologic, diagnostic, and therapeutic aspects of Hodgkin and non-Hodgkin lymphoma. IUCLS will gather both domestic and international clinicians and researchers specializing in the treatment of patients with lymphoma. This event gives opportunities for providers to explore vital information on clinical updates and research in order to ensure they are using the latest treatment options in their practice.
Target Audience
The symposium has been designed for medical hematologists/oncologists, radiation oncologists, pathologists, surgical oncologists, fellows-in-training, oncology nurses, and allied health professionals committed to the diagnosis and treatment of lymphoma.
Learning Objectives
At the conclusion of this activity, participants will be able to:
- Evaluate the latest treatment strategies for patients with indolent and aggressive forms of B-cell non-Hodgkin lymphoma, such as follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma;
- Assess the safety and efficacy of current and emerging therapeutic approaches for the care of patients with Hodgkin lymphoma;
- Compare and contrast the various patient and disease-related factors that may impact therapeutic decisions for patients with newly diagnosed and previously treated CLL;
- Discuss approaches to the care of patients with rare lymphoma subtypes, including Burkitt lymphoma and peripheral T-cell lymphoma;
- Develop strategies to communicate with and utilize the entire multidisciplinary team during the continuum of care of patients with lymphoma.
Accreditation and Credit Designation
Physician Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Chicago Pritzker School of Medicine and Bio Ascend LLC. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 13.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit
University of Chicago Medicine is accredited as a provider of continuing nursing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. Participants who successfully complete the entire activity and complete an evaluation form will earn 13.75 contact hours.
American Board of Internal Medicine MOC Part II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Other Participant Credit
Other participants will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCME, please consult your professional licensing board.
Educational Grants/Commercial Support
Educational grant funding has been generously provided by: ADC Therapeutics, AstraZeneca, Genentech, Genmab, Novartis
We also thank our sponsors/exhibitors:
Platinum: BeiGene, Inc.
Gold: AstraZeneca, Lilly
Silver: ADC Therapeutics, Apellis Pharmaceuticals, Bristol Myers Squibb, Genentech, Inc., Genmab, Ipsen Pharma, Kite, A Gilead Company, Novartis, Pfizer, Inc.
Contributing: Alexion
Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, the University of Chicago Pritzker School of Medicine requires authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Course Faculty
The following faculty and planners have disclosed that they have no relevant financial relationships with ACCME defined commercial interests in the past twelve months:
Kirk E. Cahill, MD
Changchun Deng, MD, PhD
Rebecca Follenweider, RN, BSN
Justine M. Kahn, MD
Kaitlin P. Kelly, PharmD, BCOP
Vaishalee P. Kenkre, MD
Tara McCabe, APN, AOCNP
Anamarija M. Perry, MD
Girish Venkataraman, MD
Lihua E. Budde, MD, PhD serves as a consultant for AstraZeneca, as an advisor for Roche, Genentech, ADC Therapeutics, AstraZeneca, BMS, Nurix, Abbvie, Janssen, and receives institutional research funding from Amgen and Merck. Dr. Budde plans to discuss the unapproved/investigational use of Mosunetuzumab in DLBCL; Mosunetuzumab is currently approved in Follicular lymphoma, and the use of Tocilizumab for CRS mitigation for bispecific antibody.
Ruemu E. Birhiray, MD serves on the speaker’s bureau and advisory board for Janssen, Pharmacyclics, Incyte, Morphosys, Regeneron, and Sanofi. Dr. Birhiray serves on the speaker’s bureau for Amgen, Puma Biotechnology, Lilly USA, Genzyme, DOVA/SOBI Pharmaceuticals, Exelixis, Inc., E.R. Squibb & Sons, L.L.C. Astra Zeneca, Diiachi Sancho, Glaxo Oncology, Seagen, CTI, and Blue Medicines, and on the advisory board for Array Biopharma, Inc., Lilly Oncology, Epizyme, TG Therapeutics, Abbvie, and Takeda.
Jennifer L. Crombie, MD serves as a consultant for Seagen, Regeneron, Kite, and Karyopharm, and receives institutional research funding from Genentech, Merck, Abbvie, and Bayer.
Andrew Evens, DO, MBA, MSc serves on the advisory board for Seattle Genetics, Incyte, Genentech, Research to Practice, Epizyme and Epizyme, Novartis, and Pharmacyclics.
Timothy Fenske, MD, MS serves as a consultant for Adaptive Biotechnologies, Lilly/LOXO, Abbvie/Pharmacyclics, and ADCT Pharmaceuticals. He serves as a speaker for AstraZeneca, Beigene, SeaGen, and Kite/Gilead.
Christopher R. Flowers, MD serves as a consultant, advisor, and speaker for AbbVie, AstraZeneca, Bayer, Beigene, BMS, Celgene, Denovo Biopharma, Foresight Diagnostics, Genentech/Roche, Genmab, Gilead, Karyopharm, Pharmacyclics/ Janssen, Seagen, and Spectrum. Dr. Flowers owns stock in Foresight Diagnostics & N Power, and receives institutional research funding from 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD Serono, Genentech/Roche, Gilead, Guardant, Iovance, Janssen, Kite, Morphosys, Nektar, Novartis, Pfizer, Pharmacyclics, and Sanofi.
Jacklyn Gideon, MSN serves on the speaker’s bureau and advisory board for BMS and Abbvie/Genmab and on the speaker’s bureau for Pharmacyclics/Janssen and Sanofi Genzyme.
Leo I. Gordon, MD serves on the advisory board for BMS and KITE, as an advisor for Ono Pharm.
Boyu Hu, MD serves as a consultant for BMS, Novartis, GenMab, Eli Lilly, and ADC Therapeutics, ImmPACT Bio, Regeneron, and Caribou Biosciences. Dr. Hu also receives institutional research funding and serves as the site principal investigator on clinical trials for Genentech, Celgene, CRISPR, Morphosys AG, Caribou Biosciences, Repare Therapeutics, Artiva Biotherapeutics, Newave, AstraZeneca, and ImmPACT Bio. Dr. Hu plans to discuss the unapproved/investigational use of AHOD2131 which is a NCTN clinical trial investigating the combination treatment of brentuximab vedotin and nivolumab for the frontline treatment of early stage Hodgkin lymphoma. Neither agent alone, nor the combination, is approved for the frontline treatment of early stage Hodgkin lymphoma outside of this clinical trial. He’ll also be discussing other clinical trials utilizing either nivolumab, pembrolizumab or brentuximab vedotin in the frontline and relapsed treatment landscapes in Hodgkin lymphoma.
Swaminathan Iyer, MD serves as a consultant and researcher for Seagen/Pfizer, CRISPR, Yingli, Acrotech, Merck, Ono, Salarius, and Legend. Dr. Iyer plans to discuss the unapproved/investigational discussion of early phase agents/CAR-T from clinical studies.
Reem Karmali, MD, MS serves on the advisory board and speaker’s bureau for BeiGene, Astra Zeneca, and Morphosys. Dr. Karmali serves as a consultant for Lilly Onc, Genmab, Abbvie, Miltenyi, BMS, and Genentech/Roche.
Adam S. Kittai, MD serves on the speaker’s bureau for BeiGene, Abbvie, and AstraZeneca, as an advisor for Beigene, Janssen, AstraZeneca, KITE, Eli Lilly, and BMS, as a consultant for Abbvie, and receives institutional research funding from BeiGene, and AstraZeneca. Dr. Kittai plans to discuss the unapproved/investigational use of drugs that are currently in clinical development, including BTK degraders.
Justin Kline, MD serves as a consultant and advisor for Kite/Gilead, Abbvie, ADC Therapeutic, and BeiGene. Dr. Kline receives institutional research funding from Merck and serves as a speaker for Curio Sciences.
Ann S. LaCasce, MD, MMSc serves on the advisory board for Kite Pharma and Seagen, and on the speaker’s bureau for Research to Practice.
Stefano Luminari, MD serves as an advisor for Roche, Beigene, BMS, Kite, Incyte, Regeneron, Abbvie, and Sobi.
Kami Maddocks, MD serves as a consultant for Abbvie, ADC Therapeutics, AstraZeneca, BMS, Gilead/Kite, and Genmab. Dr. Maddocks did serve as a consultant for Genentech, Incyte, Lilly, and Morphosys.
Enrica Marchi, MD, PhD serves as a scientific advisor to Vittoria Biotherapeutics, receives institutional research funding from Merck, Celgene/BMS, Dre Bio, Astex Pharmaceutical, and Kymera Therapeutics, and serves on the data safety monitoring committee for Everest Clinical research.
Neha Mehta-Shah, MD, MSCI serves on the advisory board and as a consultant for Astra Zeneca, Genentech/Roche, Secura Bio, and Daiichi Sankyo and receives institutional research funding from BMS, C4 Therapeutics, Celgene, Dizal Pharmaceuticals, InCyte Corp, Innate Pharmaceuticals, Yingli Pharmaceuticals, and Johnson & Johnson/Janssen. Dr. Mehta-Shah served as an advisor and consultant for Kyowa Hakko Kirin Co, Ltd, Pfizer, and Verastem.
Susan K. Parsons, MD, MRP serves as a consultant for Seagen.
Chelsea C. Pinnix, MD, PhD receives institutional research funding from Merck & Co and serves on the advisory board for ASTRO.
Joanna M. Rhodes, MD MSCE serves as a consultant for Abbvie, ADC Therapeutics, Beigene, Genentech, GenMab, Loxo Oncology, Epizyme, Morphosys, Pharmacyclics, and SeaGen. Dr. Rhodes also serves on the advisory board for Abbvie, Beigene, and Janssen, receives honorarium for speaking from Aptitude, Curio and institutional research funding from Acerta, Epizyme, Janssen, Loxo Oncology, Oncternal, Pharmacyclics, and Velosbios. Dr. Rhodes plans to discuss the upapproved/investigational use of the combination of BTK inhibitor such as ibrutinib with venetoclax.
Gilda Grace Rivera, APN served as on the advisory board for Seagen.
David A. Russler-Germain, MD, PhD serves on the advisory board for AstraZeneca and receives institutional research funding from Genentech. Dr. Russler-Germain plans to discuss the unapproved/investigational use of bispecific antibodies in the treatment of follicular lymphoma which will include discussion of the FDA approved products and indications, as well as interim clinical trial data presented as abstracts at recent biomedical congresses, exploring new indications for these same drugs.
Sarah C. Rutherford, MD serves as a consultant for ADC, BMS, Genmab, Karyopharm, Kite, and Seagen, and receives institutional research funding from Constellation, Genentech/Roche, and Karyopharm.
Sonali Smith, MD, FASCO served as a consultant and on the advisory board for Genmab, Ono Pharmaceuticals, Gilead, and BMS. Dr. Smith plans to discuss approved agents in unapproved settings or unapproved drugs in investigational settings. She will disclose these if present within a case study.
Jacob D. Soumerai, MD serves as a consultant for LexoLilly, Seattle Genetics, Genetech/Roche, Bristol Myers Squibb, Beigene, and AstraZeneca. Dr. Soumerai also receives institutional research funding from Adaptive Biotechnologies, Boston Scientific, GSK, Moderna, Takeda, TG Therapeutics, Genentech/Roche, and Beigene.
Andrew D. Zelenetz, MD, PhD serves as a consultant for Genentech/Roche, Celgene, Gilead, Janssen, Amgen, Novartis, Adaptive Biotech, MorphoSys, Abbvie, AstraZeneca, and MEI Pharma. Dr. Zelenetz also receives institutional research funding from MEI Pharma, Genentech/Roche, Beigene, and serves as a principal investigator for SPORE and on the data monitoring committee for Beigene, BMS, Celgene, Juno – DMC Member.
The staff of the Center for Continuing Medical Education and Bio Ascend have disclosed that they have no relevant financial relationships with ACCME defined commercial interests
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclaimer
The views expressed in this activity are those of the individual speaker. It should not be inferred or assumed that they are expressing the views of any pharmaceutical or product/device manufacturer, provider of commercial services, or The University of Chicago. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently prescribed.
Copyright © 2024 University of Chicago. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from The University of Chicago Center for Continuing Medical Education.